ゲンタミシン 化学特性,用途語,生産方法
効能
抗生物質, タンパク質合成阻害薬
解説
ゲンタマイシンC,Micromonospora purpureaまたはM.echinosporaが産生するアミノ配糖体抗生物質で，ゲンタマイシン C1：C21H43N5O7(477.59)，C2：C20H41N5O7(463.57)，および C1a：C19H39N5O7(449.54)の混合物．白色の粉末．融点102～108 ℃．[α]25D＋146°(水)．水溶性塩基性物質．細菌のリボソームの30Sと50Sの両サブユニットに結合してタンパク質合成の開始反応を阻害し，コドンの読み間違いも起こす．グラム陽性菌および緑膿菌を含むグラム陰性菌に殺菌的に作用する．硫酸塩が注射および外用で使用される．嫌気的な環境や酸性では不活性で，嫌気性菌や膿瘍の治療には使わない．副作用は，腎毒性と耳毒性で，アミノグリコシド系抗生物質のなかでも強いほうである．硫酸塩はLD50 75 mg/kg(マウス，静注)．
説明
Gentamicin is a mixture of several antibiotic components produced by fermentation of Mi cromonospora
purpurea and other related soil microorganisms (hence its name is spelled with an “i” instead of a “ y”).
Gentamicins C-1, C-2, and C-1a are most prominent. Gentamicin is the most important of the aminoglycoside
antibiotics still in use. Gentamicin was, for example, one of the first antibiotics to have significant activity
against Pseudomonas aeruginosa infections. This water-loving, opportunistic pathogen frequently is
encountered in burns, pneumonias, and urinary tract infections.
化学的特性
Amorphous solid. Freely soluble in water, pyridine, acid solutions; moderately
soluble in methanol, ethanol, and acetone;
practically insoluble in benzene and halogenated
hydrocarbons.
使用
antibacterial
適応症
This antibiotic is a combination of three related aminoglycoside
agents obtained from cultures of Micromonospora purpurea and acts
by interfering with the bacterial synthesis of protein. It prevents bacterial protein
synthesis by irreversibly binding to 30S ribosomal subunits. Its antibiotic spectrum
is similar to that of neomycin, and cross-resistance does occur. Gentamicin is active
against gram-negative organisms including Escherichia coli and a high percentage
of strains of Pseudomonas species and other gram-negative bacteria. Proteus
organisms show a variable degree of sensitivity. Some gram-positive organisms,
including S. aureus and group A β-hemolytic streptococci, are also affected.
In
general, higher concentrations are needed to inhibit streptococci than those needed
to inhibit staphylococci and many gram-negative bacteria. It is inactive against
fungi, viruses, and most anaerobic bacteria. The most important use of gentamicin
is in the treatment of systemic gram-negative infections, particularly those due to
Pseudomonas organisms. Widespread use is unwarranted not only because equally
effective drugs are available but also because of the risk of increasing the background
of gentamicin-resistant organisms. Allergic reactions to gentamicin are unusual but
may occur with prolonged use. Cross-reactivity with neomycin may occur.
世界保健機関（WHO）
Gentamicin has been used inin situ preparations for the treatment
of minor infections. Antibiotics that are also available for systemic use are not
considered acceptable for topical use because of the risk of development of
resistance. Neomycin is the topical aminoglycoside listed in the WHO Model List
of Essential Drugs.
抗菌性
It is active against staphylococci, but streptococci
are at least moderately resistant. Gram-positive bacilli, including
Actinomyces and Listeria spp., are moderately susceptible,
but clostridia and other obligate anaerobes are resistant. There
is no clinically useful activity against mycobacteria. It is active
against most enterobacteria, including Citrobacter, Enterobacter,
Proteus, Serratia and Yersinia spp., and against some other aerobic
Gram-negative bacilli including Acinetobacter, Brucella,
Francisella and Legionella spp., although its in-vitro activity
against intracellular parasites such as Brucella spp. is of doubtful
usefulness. It is active against Ps. aeruginosa and other members
of the fluorescens group, but other pseudomonads are
often resistant and Flavobacterium spp. are always resistant.
The MIC for susceptible strains of Ps. aeruginosa can vary
more than 300-fold with the Mg2+ content of the medium.
Activity against Ps. aeruginosa is also significantly lower in serum
or sputum than in ion-depleted broth, as a result both of binding
(more in sputum than in serum) and antagonism by ions.
The action is bactericidal and increases with pH, but to different
degrees against different bacterial species. Marked bactericidal
synergy is commonly demonstrable with β-lactam
antibiotics, notably with ampicillin or benzylpenicillin against
E. faecalis, and with vancomycin against streptococci and
staphylococci. Bactericidal synergy with β-lactam antibiotics
can also be demonstrated in vitro against many Gram-negative
rods, including Ps. aeruginosa. Antagonism with chloramphenicol
occurs in vitro, but this is of doubtful clinical significance.
Like other aminoglycosides, gentamicin is degraded in the
presence of high concentrations of some β-lactam agents.
獲得抵抗性
Resistant strains of staphylococci, enterobacteria, Pseudomonas
and Acinetobacter spp. have been reported from many centers,
often from burns and intensive care units where the agent has been used extensively. Overall prevalence rates of resistance
in various countries range from 3% to around 50% for Gramnegative
organisms. Countries in which control of the prescription
of antibiotics is lax often have very high rates.
Acquired resistance in Gram-negative organisms is usually
caused by aminoglycoside-modifying enzymes. The prevalence
of the different enzymes varies geographically. ANT(2″)
is most common in the USA, but in Europe various forms
of AAC(3), particularly AAC(3)-II, are common. ANT(2″)
is also common in the Far East, usually accompanied by
AAC(6′). Strains that owe their resistance to a non-specific
decrease in uptake of aminoglycosides have been involved
in outbreaks of hospital-acquired infection, and are cross-
resistant to all aminoglycosides.
Resistance in staphylococci and high-level resistance in
enterococci is usually caused by the bifunctional APH(2″)-
AAC(6′) enzyme. Other aminoglycoside-modifying enzymes
do not contribute greatly to gentamicin resistance. Gentamicinresistant
staphylococci began to emerge in the mid-1970s. Rates
of resistance in the UK are around 2.5% in methicillin-sensitive
Staph. aureus, 9% in MRSA and 23–73% in coagulase-negative
staphylococci depending on methicillin susceptibility.
High-level resistance to gentamicin (MIC >2000 mg/L) in
E. faecalis is widespread, accounting for around one-third of
blood culture isolates in some places. Penicillin does not exert
synergistic bactericidal activity against such strains, although the
combination of penicillin with streptomycin may remain active.
High-level gentamicin resistance in E. faecium is much less
common,
but has been reported in the UK, the USA and Asia.
臨床応用
In severe sepsis of unknown origin, gentamicin has been traditionally
combined with other agents. However, monotherapy
has been shown to be as effective as combination therapy.
In systemic Ps. aeruginosa infections it is advisable to combine
gentamicin with an antipseudomonal penicillin or cephalosporin,
owing to likelihood of gentamicin resistance.
Suspected or documented Gram-negative septicemia, particularly when
shock or hypotension is present
Enterococcal endocarditis (with a penicillin)
Respiratory tract infection caused by Gram-negative bacilli
Urinary tract infection
Bone and soft-tissue infections, including peritonitis, burns complicated
by sepsis and infected surgical and traumatic wounds
Serious staphylococcal infection when other conventional antimicrobial
therapy is inappropriate
Gentamicin drops are used for conjunctival infections and for
infections of the external ear. The drug is also used in orthopedic
surgery in bone cements. In these applications systemic
concentrations achieved are negligible and toxicities are
restricted to local effects.
In the elderly and those with renal impairment the dosage
must be suitably modified.
安全性プロファイル
Poison by intravenous,
intraperitoneal, intramuscular, and subcuta neous routes. Mildly toxic by ingestion. Ex perimental teratogenic and reproductive
effects. Mutation data reported. Human
systemic effects: change in motor activity,
changes in vestibular functions, dlstorted
perceptions, eye hemorrhage, hallucinations,
hdney changes, motor activity changes,
trigeminal nerve sensory changes, vestibular
function changes, visual field changes. Af fects the peripheral nervous system by intra venous route. An antibiotic. When heated to
decomposition it emits acrid smoke and
irritating fumes. See also other gentamycin
entries.
ゲンタミシン 上流と下流の製品情報
原材料
準備製品